Pramlintide-metreleptin combination therapy

Drug Profile

Pramlintide-metreleptin combination therapy

Alternative Names: AC 137-164594

Latest Information Update: 24 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Adipokines; Anorectics; Proteins
  • Mechanism of Action Adipokine receptor agonists; Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this programme
  • 04 Aug 2011 Discontinued - Phase-II for Obesity in USA (SC)
  • 17 Mar 2011 Amylin and Takeda voluntarily suspend clinical activities in a phase II trial (NCT01235741) in Obesity in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top